Oral idarubicin in measurable gastric cancer.
Seventeen patients with advanced gastric adenocarcinoma, previously untreated with chemotherapy, have been included in a Phase II study with idarubicin (IDA), 15 mg/m2/day, orally, for three consecutive days every 3 weeks. All cases had measurable disease. Sixteen of 17 patients are evaluable for response. Complete or partial responses were not observed. Two patients had partial response less than 50%, one patient no change, and the remaining 13 patients disease progression. The median leukocytes and platelets nadir was 3600 and 186,000/mm3, respectively. Gastrointestinal toxicity was mild. The median total cumulative dose of IDA was 90 mg/m2 (range 45-180 mg/m2). Clinical cardiac toxicity was not observed. IDA, at the dose and by the route used, is not active in gastric cancer.
Abad-Esteve
A
A
Hospital Germans Trias i Pujol, Badalona, Spain.
Diaz-Rubio
E
E
Jimeno
J M
JM
Rosell
R
R
Villar
A
A
Gonzalez-Larriba
J L
JL
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
D015255:Idarubicin